Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr

Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024

Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr

Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024

Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr

Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024

Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr

Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024

Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024

Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr

Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally